Related Experiment Video
Updated: May 26, 2026
13:12
Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
Published on: August 12, 2019
Mapping the road forward in Alzheimer's disease.
David M Holtzman1, Alison Goate, Jeffrey Kelly
1Department of Neurology, Washington University, St. Louis, MO 63110, USA. holtzman@neuro.wustl.edu
Science Translational Medicine
|December 23, 2011
Summary
Alzheimer's disease (AD) research faces challenges despite scientific understanding. Recommendations from experts aim to accelerate progress in genetics, clinical trials, and cell biology for future therapies.
Area of Science:
- Neuroscience
- Genetics
- Cell Biology
Background:
- Alzheimer's disease (AD) is the leading cause of dementia, posing a significant global health challenge.
- Current scientific understanding of AD has not yet yielded effective methods for disease prevention, delay, or slowing.
- Urgent need for innovative strategies to combat the escalating public health crisis associated with AD.
Framework:
- Recommendations emerged from the 2011 Abelson meeting, involving diverse scientific experts.
- Key discussion areas included genetics, clinical trial design, and protein aggregation mechanisms.
- Focus on the cell biology of the nervous system to understand AD pathogenesis.
Implementation:
- The meeting fostered collaboration and knowledge exchange among leading AD researchers.
- Identified critical research gaps and prioritized future scientific endeavors.
- Proposed actionable steps to overcome existing barriers in AD research.
Implications:
- The recommendations are expected to invigorate research progress in Alzheimer's disease.
- Aims to enhance the development of effective therapeutic interventions for AD.
- Potential to significantly improve patient outcomes and reduce the global burden of dementia.
More Related Videos
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.